Lung cancer is a common disease and the leading cause of cancer-related mortality, with
non-small cell lung cancer (NSCLC) accounting for the majority of cases. Following …

The integral role of positron-emission tomography (PET) using the glucose analog tracer
fluorine-18 fluorodeoxyglucose (FDG) in the staging of non-small cell lung cancer (NSCLC) …

This communication presents an update on the current role of positron emission tomography-
computed tomography (PET-CT) in the various clinical decision-making steps in lung …

For several years, molecular imaging with 18F‐fluorodeoxyglucose positron emission
tomography (FDG‐PET) has become part of the standard of care in presurgical staging of …

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer morbidity and
mortality. Adjuvant chemotherapy improves survival in resected early-stage NSCLC …

Lung cancer is the cause of 32% of all male cancer deaths and 25% of all female cancer
deaths. Because the prognosis depends on early diagnosis and staging, continuous …

Since its introduction in 1974, positron emission tomography (PET) has gained widespread
use, especially in diagnosis and staging of lung cancer. In this respect, 18F …

Integrated positron emission tomography/computed tomography (PET/CT) has many
advantages over solitary PET and CT, which has led it to become an increasingly …

Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis
and staging of lung cancer, but is also appealing for assessment of prognosis and treatment …

Positron emission tomography (PET)/computed tomographic scanning, using 18F-2-deoxy-
D-glucose, complements conventional imaging evaluation of patients with lung cancer. The …